







Chondrotoxicity of intra-articular injection products

Nicola Manocchio¹, Alberto Migliore², Calogero Foti¹

- 1. Physical and Rehabilitation Medicine, Tor Vergata University, Rome, Italy
 - 2. Unit of Rheumatology, Ospedale S. Pietro FBF, Rome, Italy

E-mail: nicola.manocchio@uniroma2.it

Author has nothing to disclose




Bucharest 24 October 2025






► Intra-articular (IA) injections are common in osteoarthritis to reduce pain and improve function





Ali Mobasheri ^{a b c d e} 💍 🖾 , Gauthaman Kalamegam ^e, Giuseppe Musumeci ^f, Mark E. Batt ^{b g}



Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study

```
Arthritis Care and Research • Article • Open Access • 2009 • DOI: 10.1002/art.24096 Chevalier X. a, k \boxtimes; Goupille P. b; Beaulieu A.D. c; Burch F.X. d; Bensen W.G. e; +5 authors
```





The most used compounds for IA injections are:

- Corticosteroids
- Local Anaesthetics
- Hyaluronic Acids (HA)
- Platelet-rich Plasma (PRP)
- Nonsteroidal Anti-inflammatory Drugs (Nsaids)
- Collagen Medical Devices
- Bisphosphonates

Like all substances used as drugs, these compounds can also have **side effects**





Articular cartilage is a delicate, avascular tissue reliant on chondrocytes for matrix synthesis and repair

- balanced tissue of 2-4 mm-thick hyaline cartilage
- no nerves and blood or lymphatics vessels
- complex extracellular matrix (ECM) and specialized cellular elements

This sophisticated composition confers the capacity to endure substantial compressive forces while enabling smooth, frictionless articulation of the joints








- ► ECM is the main structure of articular cartilage
 - ► Water, collagen, proteoglycans, other noncollagenous proteins and glycoproteins are the main ECM constituents

Type II collagen fibers (90%) are stabilized by other less frequently appearing collagen types

ECM dry components











Highly specialized and metabolically active cells

Derived from mesenchymal stem cells

Involved in formation, upkeep, turnover and restoration of the ECM

Create specialized microenvironments



Bucharest 2025





Chondrocytes play a central role for ECM and articular cartilage

Synthesize ECM components and several enzymes responsible for its remodelling


As vascularization is lacking: primarily anaerobic metabolism

Metabolic activity can be altered by cytokines, growth factors, regulatory peptides, joint motion and load























ARTICULAR CARTILAGE IS A
PARTICULARLY DELICATE TISSUE,
VERY DIffiCULT TO REPAIR

CHONDROCYTES HAVE A CENTRAL ROLE FOR ECM SYNTHESIS AND REPAIR

CONCERN EXISTS ABOUT DRUG-INDUCED CHONDROTOXICITY COMPROMISING CARTILAGE INTEGRITY AND LONG-TERM OUTCOMES



To review chondrotoxic effects of the most used IA products



Bucharest 2025










Review

Chondrotoxicity of Intra-Articular Injection Treatment: A Scoping Review

Carmelo Pirri ¹, Andrea Sorbino ², Nicola Manocchio ², Nina Pirri ³, Antonio Devito ⁴, Calogero Foti ² and Alberto Migliore ^{5,*}

Paper available here |









- ► An extensive literature search was performed using the following MeSH terms on **PubMed, Scopus and Web of Science**:
 - ▶ "chondrotoxicity", "intraarticular injection", "corticosteroids", "steroids", "hyaluronate or hyaluronic acid", "non-steroidal anti-inflammatory drug", "anaesthetic", "platelet rich plasma", "collagen medical devices" and "bisphosphonates".

Studies were included if

in vivo or in vitro

evaluated chondrotoxicity

published in English




RESULTS

Bucharest 2-4 October 2025











In total
65 studies
were included in the review

- Corticosteroids: 33
- Local Anesthetics: 18
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): 5
- Hyaluronic Acid (HA): 7
- Platelet-Rich Plasma (PRP): 2

No paper was retrieved regarding collagen medical devices or bisphosphonates



RESULTS - Corticosteroids (n = 33)







A total of 33

papers
regarding
corticosteroids
were retrieved

14 on human subjects, 17 on animals, and 2 comparisons (humans and animals)

16 in vivo studies, 16 in vitro and 1 ex vivo

Explored drugs: Betamethasone, Methylprednisolone, Triamcinolone, Dexamethasone, Hydrocortisone

19 (58%) studies expressed evidence about corticosteroids' potential chondrotoxicity



RESULTS - Corticosteroids (n = 33)

Bucharest 2-4 October 2025





Corticosteroids are frequently used due to their antiinflammatory effects

Dose- and frequency- dependent chondrotoxicity (except for triamcinolone)

Corticosteroids
can improve
functional
outcomes and
quality of life in
painful
conditions

Both in vitro and in vivo studies in humans and animals showed variable but concerning cartilage damage



RESULTS - Local Anaesthetics (n = 18)







A total of 18 papers regarding local anaesthetics were retrieved

4 on human subjects, 14 on animals

6 in vivo studies, 12 in vitro

$$H_3C$$
 H_3C
 H_3C

lidocaine

Explored drugs: Bupivacaine, Lidocaine, Ropivacaine, Mepivacaine

17 (95%) studies expressed evidence about local anaesthetics' potential chondrotoxicity



RESULTS - Local Anaesthetics (n = 18)

Bucharest 2-4 October 2025





Widely used to achieve analgesia (often combined with corticosteroids), crucial for the success of an IRP

Ropivacaine and liposomal formulations of bupivacaine appeared less toxic

Bupivacaine, lidocaine, and ropivacaine showed doseand timedependent chondrotoxicity

Vitamin C may mitigate chondrotoxic effects

Importance of limiting dose and frequency





A total of 5 papers regarding NSAIDs were retrieved

3 on human subjects, 2 on animals

1 in vivo studies, 4 in vitro

$$CH_3$$
 CH_3 OH

Explored drugs: Dexketoprofen, Ketorolac, Naproxen, Ibuprofen, Aceclofenac, Diclofenac

4 (80%) studies expressed evidence about NSAIDs potential chondrotoxicity



RESULTS - NSAIDs (n = 5)

Bucharest 2-4 October 2025





Widely used in OA for oral administration to reduce pain and functional impairments

IA injections not common - this route might reduce systemic side effects and increase local efficacy

Limited and inconsistent data on chondrotoxicity

Ketorolac and
Naproxen showed
potential cartilage
damage

Aceclofenac showed potential positive effects on glycosaminoglycan synthesis

Ibuprofen showed limited toxicity



RESULTS – Hyaluronic Acid (n = 7)








A total of 7
papers
regarding
Hyaluronic
Acid were
retrieved

2 on human subjects, 5 on animals

All the studies were conducted with in vitro models



Focused on assessing HA efficacy in reducing chondrotoxicity caused by other drugs (carprofen, corticosteroids and anaesthetics)

All the studies showed potential benefits by HA in reducing other compounds' chondrotoxicity



RESULTS - Hyaluronic Acid (n = 7)

Bucharest 2-4 October 2025





One of the most used compounds for IA injections in OA

HA promotes chondrocyte survival and function

HA appears safe and protective against the toxicity of other drugs Only in vitro
data about
chondrotoxicity,
limiting
translation to
real world
scenario



RESULTS - PRP (n = 2)









2 papers on PRP were retrieved, both on humans

Beitzel et al. (2013) showed increased cell proliferation and viability in tendon and cartilage after PRP

Limited evidence available, more research needed to clarify PRP effects (beneficial or harmful)

PRP may represent a therapeutic option with low chondrotoxicity risk



CONCLUSION





- ▶ Heterogeneity in study protocols and methods limits definitive conclusions
- ► Chondrotoxicity seems influenced by dose, frequency, and drug combinations
- ► Corticosteroids (except triamcinolone), local anesthetics (except ropivacaine and liposomal forms), and some NSAIDs (ketorolac, naproxen) show higher risk profiles
- ► HA and PRP show promise as safer options, but more research needed in real world
- ► Standardized, larger studies are urgently needed









Thank you for your attention!









Linked in ®



hank you for your attention!









Chondrotoxicity of intra-articular injection products

Nicola Manocchio¹, Alberto Migliore², Calogero Foti¹

- 1. Physical and Rehabilitation Medicine, Tor Vergata University, Rome, Italy
 - 2. Unit of Rheumatology, Ospedale S. Pietro FBF, Rome, Italy

E-mail: nicola.manocchio@uniroma2.it